Published mark
SELLAS Life Sciences Group, Inc.
NASDAQ: SLS. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:3e059f35-4e1e-4ea1-811b-b95f638f1a96
- SEC CIK
- 0001390478
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 22, 2026
- Newest evidence
- Apr 23, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Angelos M. Stergiou, M.D., Sc.D. h.c.President and Chief Executive Officer
- Chair
- John Varian
- Independent
- Not published5 directors published
- Published claims
- 402 distinct sources
- Evidence records
- 50 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 5 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Angelos M. Stergiou seat on SELLAS Life Sciences Group, Inc., effective 2026-04-23.
EffectiveEffective Apr 23, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Senior Vice President, Chief Financial Officer | James Burns | Apr 2026 | current | Source reportedE4 |
| President and Chief Executive Officer | Angelos M. Stergiou, M.D., Sc.D. h.c. | Not captured | unknown | Source reportedE2 |
| Senior Vice President and Chief Development Officer | Dragan Cicic, M.D. | Not captured | unknown | Source reportedE2 |
| Senior Vice President and Chief Financial Officer | John T. Burns | Not captured | unknown | Source reportedE2 |
Board of directors
Evidence5 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Angelos M. Stergiou | Independence not published | 2026 | Audit Committeecompensation committeeNominating and Corporate Governance CommitteeScience Committee | Source reportedE3 |
| David A. Scheinberg | Independence not published | 2017 | Audit Committeecompensation committeeNominating and Corporate Governance CommitteeScience Committee | Source reportedE3 |
| Jane Wasman | Independence not published | 2017 | Audit Committeecompensation committeeNominating and Corporate Governance CommitteeScience Committee | Source reportedE3 |
| Katherine Bach Kalin | Independence not published | 2022 | Audit Committeecompensation committeeNominating and Corporate Governance CommitteeScience Committee | Source reportedE3 |
| Robert L. Van Nostrand | Independence not published | 2017 | Audit Committeecompensation committeeNominating and Corporate Governance CommitteeScience Committee | Source reportedE3 |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | Not independent | Not published | President and Chief Executive Officer | Source reportedE2 |
| David A. Scheinberg, M.D., Ph.D. | Independent | Not published | None published | Source reportedE2 |
| John Varian | IndependentChair | Not published | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit Committee | Not published | Angelos M. Stergiou, David A. Scheinberg, Jane Wasman, Katherine Bach Kalin, Robert L. Van Nostrand | Not described in the published record |
| compensation committee | Not published | Angelos M. Stergiou, David A. Scheinberg, Jane Wasman, Katherine Bach Kalin, Robert L. Van Nostrand | Not described in the published record |
| Nominating and Corporate Governance Committee | Not published | Angelos M. Stergiou, David A. Scheinberg, Jane Wasman, Katherine Bach Kalin, Robert L. Van Nostrand | Not described in the published record |
| President and Chief Executive Officer | Not published | Angelos M. Stergiou, M.D., Sc.D. h.c. | Not described in the published record |
| Science Committee | Not published | Angelos M. Stergiou, David A. Scheinberg, Jane Wasman, Katherine Bach Kalin, Robert L. Van Nostrand | Not described in the published record |
Committee RecordAudit Committee: Chair not stated; Members Angelos M. Stergiou; David A. Scheinberg; Jane Wasman; Katherine Bach Kalin; Robert L. Van Nostrand
Committee AppointmentAngelos M. Stergiou: member, Audit Committee
Committee AppointmentDavid A. Scheinberg: member, Audit Committee
Committee AppointmentJane Wasman: member, Audit Committee
Committee AppointmentKatherine Bach Kalin: member, Audit Committee
Committee AppointmentRobert L. Van Nostrand: member, Audit Committee
Committee Recordcompensation committee: Chair not stated; Members Angelos M. Stergiou; David A. Scheinberg; Jane Wasman; Katherine Bach Kalin; Robert L. Van Nostrand
Committee AppointmentAngelos M. Stergiou: member, compensation committee
Committee AppointmentDavid A. Scheinberg: member, compensation committee
Committee AppointmentJane Wasman: member, compensation committee
Committee AppointmentKatherine Bach Kalin: member, compensation committee
Committee AppointmentRobert L. Van Nostrand: member, compensation committee
Committee RecordNominating and Corporate Governance Committee: Chair not stated; Members Angelos M. Stergiou; David A. Scheinberg; Jane Wasman; Katherine Bach Kalin; Robert L. Van Nostrand
Committee AppointmentAngelos M. Stergiou: member, Nominating and Corporate Governance Committee
Committee AppointmentDavid A. Scheinberg: member, Nominating and Corporate Governance Committee
Committee AppointmentJane Wasman: member, Nominating and Corporate Governance Committee
Committee AppointmentKatherine Bach Kalin: member, Nominating and Corporate Governance Committee
Committee AppointmentRobert L. Van Nostrand: member, Nominating and Corporate Governance Committee
Committee RecordScience Committee: Chair not stated; Members Angelos M. Stergiou; David A. Scheinberg; Jane Wasman; Katherine Bach Kalin; Robert L. Van Nostrand
Committee AppointmentAngelos M. Stergiou: member, Science Committee
Committee AppointmentDavid A. Scheinberg: member, Science Committee
Committee AppointmentJane Wasman: member, Science Committee
Committee AppointmentKatherine Bach Kalin: member, Science Committee
Committee AppointmentRobert L. Van Nostrand: member, Science Committee
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerAngelos M. Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingSLS (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 22, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameSELLAS Life Sciences Group, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- James BurnsSenior Vice President, Chief Financial Officercompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:15
- Angelos M. Stergiou, M.D., Sc.D. h.c.President and Chief Executive Officer; Director, President and Chief Executive Officercompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:13, company:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:7
- Dragan Cicic, M.D.Senior Vice President and Chief Development Officercompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:14
- John T. BurnsSenior Vice President and Chief Financial Officercompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:16
- Angelos M. StergiouDirectorcompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:6
- David A. ScheinbergDirectorcompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:8
- Jane WasmanDirectorcompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:10
- Katherine Bach KalinDirectorcompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:11
- Robert L. Van NostrandDirectorcompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:12
- David A. Scheinberg, M.D., Ph.D.Directorcompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:9
- John VarianChair of the Boardcompany:3e059f35-4e1e-4ea1-811b-b95f638f1a96:leadership_role:5
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 5 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 22, 2026. Cited by 4 Claims.
- E2sec def 14a. Published Apr 23, 2026. Retrieved Sep 13, 2026. Cited by 6 Claims.
- E3sec proxy. Published Apr 23, 2026. Retrieved Sep 2, 2026. Cited by 5 Claims.
- E4sec filing. Published Apr 23, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E5governance_people_committees. sec proxy. Cited by 24 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 22, 2026- Angelos M. Stergiou seat on SELLAS Life Sciences Group, Inc., effective 2026-04-23.
- James Burns executive of SELLAS Life Sciences Group, Inc., effective 2026-04-23.
- Katherine Bach Kalin seat on SELLAS Life Sciences Group, Inc., effective 2022-01-01.
- David A. Scheinberg seat on SELLAS Life Sciences Group, Inc., effective 2017-01-01.
- Jane Wasman seat on SELLAS Life Sciences Group, Inc., effective 2017-01-01.
- Robert L. Van Nostrand seat on SELLAS Life Sciences Group, Inc., effective 2017-01-01.